PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

inder the Paperwork Recheston Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

	Complete if Known	
Application Number	To be assigned	
Filing Date	November 3, 2003	
First Named Inventor	Timmermans et al.	
Attorney Docket Number	2183-5581.1US	

		Document Number		NT DOCU	me of Patentee or Applicant of			
nitials *	Cite No. ¹	Number - Kind Code ² (if known)	Publication I		Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant	
1/2		US-4,683,194	7-1987		Saiki et al.	г даны турса		
7		US- 5,104,792	04-14-199	2	Silver et al.			
		US- 5,106,727	04-21-199	2	Hartley et al.		***	
		US- 5,607,834	3-1997		Bagwell			
		US- 5,948,649	09-07-199	9	Stewart et al.	<u> </u>		
		US- 2001021518	09-13-200)1	Goudsmit et al.			
		US- 6,027,880	2-2000		Cronin et al.	 		
T		US- 6,521,428	02-2003		Senapathy			
		US- 2003/0022194 A1	01-2003		Erlander et al.			
		US- 2003/0003488 A1	01-2003		Ramakrishnan			
		US- 2003-0099933 A1	05-2003		Cote et al.			
		US- 2002-0169562 A1	11-2002		Stephanopoulos et al.			
		US- 2002-0049176 A1	04-2002		Anderson et al.			
		US-2002-0048763 A1	04-2002		Penn et al.			
		US-5,569,754 A	10-1996		Williams et al.			
4		US-6,221,600 B1	04-2001		MacLeod et al.			
1 5		US-6,232,065 B1	05-2001		Robinson et al.			
ر حول			FOREIG	N PATENT	DOCUMENTS			
xaminer	Cite	Foreign Patent Doc		1	Name of Patentee or	Pages, Columns, Lines,		
Initials*	No.1	0 0		Publication Date	te Applicant of Cited	Where Relevant Passages or		
P		Country Code ³ - Number ⁶ - Kind C	ode" (if known)	MM-DD-YYY	Document	Relevant Figures Appear	T ⁶	
N.		WO 96 15264	!	05-23-199	JSD Technologies Ltd.			
		WO 97 30062	2	08-21-199	Amsterdam Suppo Diagnostics B.V.	rt		
		WO 98 0257	5	01-22-199				
		WO 01/51661	A2	07-19-200	Amsterdam Suppo	n l		
	<u> </u>	VVO 01/01/001 A2		0. 10 200	Diagnostics B.V. Life Technologies			
_}		EO 0466520	EO 0466520		2 Inc.			
		WO 02/20571	03-2002	Goudsmit et al.				
		WO 96/4090	WO 96/40902					
		WO 02/46470	A2	06-13-200	Primagen B.V.			
		WO 96/06191	A2	02-29-199	Akzo Nobel N.V.			
					Ramot University Authority for Applie			
		WO 97/39149 /	A I	10/23/1997	Research and Industrial Development, Ltd.			
\mathcal{I}		WO 98/17826	AI	04/30/1998				
/ 1 >	l	WO 99/66075	A2	12/23/1999	Mitokor			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual ease. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Substitute for form 1449A/PTO					Complete if Known				
	INEO	D M A T	יות וארטוי	SCLOSURE	Application Number	To be assigned				
					I Filing Date	November 3, 2003				
	STATEMENT BY APPLICANT				First Named Inventor	Timmermans et al.				
•					Group Art Unit	To be assigned 1630				
	(use as many sheets as necessary)				Examiner Name	To be assigned CM Sch'				
	Sheet	2	of	3	Attorney Docket Number	2183-5581.1US				

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner nitials •	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
X		McGRATH et al., Sequence analysis of DNA randomly amplified from the Saccharomyces cerevisiae genome, Molecular and Cellular Probes, 1998, pp. 397-405, Vol. 12.	
		ROSE et al., Consensus-degenerate hybrid oligonucleotide primers for amplification of distantly related sequences, Nucleic Acids Research, 1998, pp. 1628-35, Vol. 26, No. 7.	
		SMITH et al., Automated differential display using a fluorescently labeled universal primer, Biotechniques, 1997, pp. 274-79, Vol. 23, No. 2.	
		GUO et al., Enhanced discrimination of single nucleotide polymorphisms by artificial mismatch hybridization, Nature Biotechnology, Vol. 15, pp. 331-335.	
		LEONE et al., Molecular beacon probes combined with amplification by NASBA enable homogeneous, real-time detection of RNA, Nucleic Acids Research, Vol. 26, No. 9, pp. 2150-55, 1998.	
		MARRAS et al., Multiplex detection of single-nucleotide variations using molecular beacons, Genetic Analysis: Biomolecular Engineering, 14, pp. 151-56, 1999.	
		MORRIS et al., Rapid Reverse Transcription-PCR Detection of Hepatitis C Virus RNA in Serum by Using the TaqMan Fluorogenic Detection System, Journal of Clinical Microbiology, Vol. 34, No. 12, pp. 2933-36, December 1996.	
		TYAGI et al., Multicolor molecular beacons for allele discrimination, Nature Biotechnology, Vol. 16, pp. 49-53, January 1998.	
		ABBOTT, A.G., et al., Quantitative variation of components of the maize mitochondrial genome between tissues and between plants with different male-sterile cytoplasms, 4 Plant Molecular Biology 233-40 (1985.	
		ANDERSON, C.M., et al., Mitochondrial Electron Transport Complexes are Decreased in Skeletal Muscle in Type II Diabetes Mellitus, Abstracts from the 59th Session, Page a259 (June 1999).	
K		BOULTWOOD J., et al., Amplification of mitochondrial DNA in acute myeloid leukaemia, 95 British Journal of Haematology, 426-31 (1996).	

	/ 11			
Examiner Signature	Wh	orla	Date Considered	5/25/06

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE rk Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known				
Application Number	To be assigned			
Filing Date	November 3, 2003			
First Named Inventor	Timmermans et al.			
Group Art Unit	To be assigned 1637			
Examiner Name	To be assigned CM Wabic			
Attorney Docket Number	2183-5581.1US			

 	r	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS			
Examiner Initia <u>ls</u> •	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the iter (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), published city and/or country where published.			
\searrow		LEE, H.K., et al., Decreased mitochondrial DNA content in peripheral blood precedes the development of non-insulin- dependent diabetes mellitus, 42 Diabetes Research and Clinical Practice 161-67 (1998).			
		LOCKHART et al., Expression monitoring by hydridization to high-density oligonucleotide arrays, Nature Biotechnology 14 (13): 1676-80 (DEC 1996).			
	,	SU, C., et al., Selective reduction of creatine kinase subunit mRNAs in striated muscle of diabetic rats, 263 American Journal of Physiology e310-e316 (1992).			
		TEPPER, C.G., "Resistance of Mitochondrial DNA to Degradation Characterizes the Apoptotic but Not the Necrotic Mode of Human Leukemia Cell Death, 52 Journal of Cellular Biochemistry 352-61 (1993).			
		WILLIAMS R.S., Mitochondrial Gene Expression in Mammalian Striated Muscle. Evidence That Variation in Gene Dosage is the Major Regulatory Event, J. Biol. Chem., 261 (26):12390-94 (1986).			
		WILLIAMS et al., Regulation of Nuclear and Mitochondrial Gene Expression by Contractile Activity in Skeletal Muscle, J. Biol. Chem., 261(1):376-80 (1986).			
		VOEHRINGER et al., Gene microarray identification of redox and mitochondrial elements that control resistance or sensitivity to apoptosis. PNAS 97(6):2680-5 (MAR 2000).			
		DeRISI et al., Exploring the metabolic and genetic control of gene expression on a genomic scale, Science, 278(5338):608-6 (OCT 1997).			
		DeRISI et al., Use of a cDNA microarrays to analyze gene expression patterns in human cancer, Nature Genetics 14(4):457-60 (DEC 1996).			
		SCHENA M., Genome analysis with gene expression microarrays, Bioessays 18(5): 427-31 (1996).			
		SCHENA et al., Parallel human genome analysis: microarray-based expression monitoring of 1000 genes, PNAS 93(20):10614-9 (OCT 1996).			
TO		SCHENA et al., Quantitative monitoring of gene expression patterns with a complementary DNA microarray, Science 270 (5235):467-70 (1995).			

Examiner Signature Date Considered T25/06

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.